Clinical trial
Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Efficacy and Safety of a Single Bolus Administration of Non-immunogenic Recombinant Staphylokinase in Patients With Intermediate High-risk Pulmonary Embolism (FORPE-2)
NCT06362746 is registered in ClinicalTrials.gov with Supergene, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Efficacy and Safety of a Single Bolus Administration of Non-immunogenic Recombinant Staphylokinase in Patients With Intermediate High-risk Pulmonary Embolism (FORPE-2)
- Lead sponsor
- Supergene, LLC
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- May 23, 2024
- Completion date
- December 1, 2028
- Enrollment
- 486 (estimated)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.